These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 24673736)

  • 21. [Application of fluorescence in-situ hybridization in diagnosis of ALK-positive non-small cell lung cancer].
    Zhou XY
    Zhonghua Bing Li Xue Za Zhi; 2013 Dec; 42(12):854-6. PubMed ID: 24507113
    [No Abstract]   [Full Text] [Related]  

  • 22. [Application of immunohistochemistry in diagnosis of ALK-positive non-small cell lung cancer].
    Du X; Zhou XY; Lü N; Li XH; Ying JM; Yang F; Li Y; Sun Y; Zhao M; Zhou LX
    Zhonghua Bing Li Xue Za Zhi; 2013 Dec; 42(12):858-60. PubMed ID: 24507115
    [No Abstract]   [Full Text] [Related]  

  • 23. Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer.
    Lee JK; Park HS; Kim DW; Kulig K; Kim TM; Lee SH; Jeon YK; Chung DH; Heo DS; Kim WH; Bang YJ
    Cancer; 2012 Jul; 118(14):3579-86. PubMed ID: 22086654
    [TBL] [Abstract][Full Text] [Related]  

  • 24. First-line therapy of mutated non-small cell lung cancer: an update.
    Stöhlmacher-Williams J
    Onkologie; 2012; 35(5):293-9. PubMed ID: 22868512
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ALK-rearranged adenosquamous lung cancer presenting as squamous cell carcinoma: a potential challenge to histologic type triaging of NSCLC biopsies for molecular studies.
    Dragnev KH; Gehr G; Memoli VA; Tafe LJ
    Clin Lung Cancer; 2014 May; 15(3):e37-40. PubMed ID: 24524823
    [No Abstract]   [Full Text] [Related]  

  • 26. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion.
    Rimkunas VM; Crosby KE; Li D; Hu Y; Kelly ME; Gu TL; Mack JS; Silver MR; Zhou X; Haack H
    Clin Cancer Res; 2012 Aug; 18(16):4449-57. PubMed ID: 22661537
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations.
    Tiseo M; Gelsomino F; Boggiani D; Bortesi B; Bartolotti M; Bozzetti C; Sammarelli G; Thai E; Ardizzoni A
    Lung Cancer; 2011 Feb; 71(2):241-3. PubMed ID: 21168933
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New targets in advanced NSCLC: EML4-ALK.
    Crystal AS; Shaw AT
    Clin Adv Hematol Oncol; 2011 Mar; 9(3):207-14. PubMed ID: 21475126
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact on the multidisciplinary team of molecular profiling for personalized therapy in non-small cell lung cancer.
    Blackhall F; Thatcher N; Booton R; Kerr K
    Lung Cancer; 2013 Feb; 79(2):101-3. PubMed ID: 23182148
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of molecular analyses in the diagnosis and treatment of non-small-cell lung carcinomas.
    Rossi G; Graziano P; Leone A; Migaldi M; Califano R
    Semin Diagn Pathol; 2013 Nov; 30(4):298-312. PubMed ID: 24342286
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The continuum of care for ALK-positive NSCLC: from diagnosis to new treatment options - an overview.
    Solomon B; Soria JC
    Ann Oncol; 2016 Sep; 27 Suppl 3():iii1-iii3. PubMed ID: 27573751
    [No Abstract]   [Full Text] [Related]  

  • 32. NSCLC molecular testing in Central and Eastern European countries.
    Ryska A; Berzinec P; Brcic L; Cufer T; Dziadziuszko R; Gottfried M; Kovalszky I; Olszewski W; Oz B; Plank L; Timar J
    BMC Cancer; 2018 Mar; 18(1):269. PubMed ID: 29523116
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer.
    Ellis PM; Blais N; Soulieres D; Ionescu DN; Kashyap M; Liu G; Melosky B; Reiman T; Romeo P; Shepherd FA; Tsao MS; Leighl NB
    J Thorac Oncol; 2011 Aug; 6(8):1379-91. PubMed ID: 21709590
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ALK testing in non-small cell lung carcinoma: what now?
    Kerr KM
    J Thorac Oncol; 2014 May; 9(5):593-5. PubMed ID: 24722149
    [No Abstract]   [Full Text] [Related]  

  • 35. [Statement of the German Society for Pathology and the working group thoracic oncology of the working group oncology/German Cancer Society on ALK testing in NSCLC: Immunohistochemistry and/or FISH?].
    von Laffert M; Schirmacher P; Warth A; Weichert W; Büttner R; Huber RM; Wolf J; Griesinger F; Dietel M; Grohé C
    Pathologe; 2016 Mar; 37(2):187-91. PubMed ID: 26984297
    [No Abstract]   [Full Text] [Related]  

  • 36. Preparing for tomorrow: molecular diagnostics and the changing nonsmall cell lung cancer landscape.
    Boyer M; Tsao MS; Jänne P; Ramalingam S; Pitman Lowenthal S; Alam M
    Asia Pac J Clin Oncol; 2014 Apr; 10 Suppl 2():2-10. PubMed ID: 24673735
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-Small Cell Lung Cancer, Version 6.2015.
    Ettinger DS; Wood DE; Akerley W; Bazhenova LA; Borghaei H; Camidge DR; Cheney RT; Chirieac LR; D'Amico TA; Demmy TL; Dilling TJ; Dobelbower MC; Govindan R; Grannis FW; Horn L; Jahan TM; Komaki R; Krug LM; Lackner RP; Lanuti M; Lilenbaum R; Lin J; Loo BW; Martins R; Otterson GA; Patel JD; Pisters KM; Reckamp K; Riely GJ; Rohren E; Schild SE; Shapiro TA; Swanson SJ; Tauer K; Yang SC; Gregory K; Hughes M;
    J Natl Compr Canc Netw; 2015 May; 13(5):515-24. PubMed ID: 25964637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Consensus on dignosis for ALK positive non-small cell lung cancer in China, the 2013 version].
    Zhang XC; Lu S; Zhang L; Wang CL; Cheng Y; Li GD; Mok T; Huang C; Liu XQ; Wang J; Wang MZ; Zhang YP; Zhou JY; Zhou XY; Lin DM; Yang JJ; Li H; Chen HQ; Zhong WZ; Wu YL
    Zhonghua Bing Li Xue Za Zhi; 2013 Jun; 42(6):402-6. PubMed ID: 24060077
    [No Abstract]   [Full Text] [Related]  

  • 39. Current and future molecular diagnostics in non-small-cell lung cancer.
    Li CM; Chu WY; Wong DL; Tsang HF; Tsui NB; Chan CM; Xue VW; Siu PM; Yung BY; Chan LW; Wong SC
    Expert Rev Mol Diagn; 2015; 15(8):1061-74. PubMed ID: 26153330
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Screening for ALK Rearrangements in Lung Cancer: Time for a New Generation of Diagnostics?
    Dagogo-Jack I; Shaw AT
    Oncologist; 2016 Jun; 21(6):662-3. PubMed ID: 27245570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.